AMEND news in Month: November 2021
-
AMEND’s 2021 Research Grants Awarded
AMEND is pleased to announce the funding of 3 research projects in its 2021 Research Fund Award round. These included the John Pettit Award for MEN1 Research.
Click here to learn more
-
AMEND Launches MEN1 Patient Experience Films on NET Cancer Day
We meet Emma, Steph and Kevin, and hear their experiences of diagnosis and treatment in MEN1, as well as how they feel that their disease may affect their futures. Each film is a separate ‘case study’ of one of our film stars. These films were launched on 10 November 2021 (NET Cancer Day).
Click here to go to the MEN1 Page and Films
-
AMEND Launches MEN2 Patient Experience Films During Thyroid Cancer Month
We meet Liz, Laura and Mandi and hear their experiences of diagnosis and treatment in MEN2A, as well as how they feel that their disease may affect their futures. Each of the three films features all three of our stars discussing these different aspects and are narrated by our Celebrity Patron, Shaun Williamson. They were launched during September 2021 (Thyroid Cancer Awareness Month).
Click here to go to the MEN2 Page and Films
-
AMEND and BTF Pen Article for SfE’s 75th Anniversary Magazine
AMEND CEO, Jo Grey, was honoured to be asked to write a piece entitled ‘Patients, Partnerships and a Pandemic’ for the Society for Endocrinology’s 75th Anniversary edition of their magazine, The Endocrinologist.
-
AMEND Attends the 2021 British Endocrine Society Meeting (BES 2021)
Jo Grey and Gill Masters were delighted to be able to attend the British Endocrine Society meeting once again, this year in Edinburgh in November.
-
2021 Annual Patient Information Day Success!
After a long 18-month delay, the AMEND Annual Patient Information Day finally went ahead in person on Saturday 16th October at the Paddington Novotel in London, with covid-19 vaccine/LFT checking before entry.
-
Selpercatinib Approved for Metastatic MTC
In September, selpercatinib (also known as LOXO) was approved in England (Cancer Drugs Fund) and Scotland (Interim Basis) for use in metastatic RET-mutation medullary thyroid cancer (MTC) as well as other RET-fusion positive thyroid cancers.